Dr. Schwartzberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Pringle Way
Ste 801
Reno, NV 89502Phone+1 775-982-5000Fax+1 775-982-2821
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1987
- Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1981 - 1983
- New York Medical CollegeClass of 1980
Certifications & Licensure
- NV State Medical License 2021 - 2025
- AR State Medical License 2002 - 2023
- MS State Medical License 1989 - 2022
- TN State Medical License 1987 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- Memphis Magazine: Top Doctors Castle Connolly, 2008-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Join now to see all
Clinical Trials
- Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma Start of enrollment: 2001 Nov 01
- Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2005 Jun 01
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy Start of enrollment: 2007 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 1120 citations2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineThomas J. Smith, James Khatcheressian, Gary H. Lyman, Howard Ozer, James O. Armitage
Journal of Clinical Oncology. 2006-07-01 - 87 citationsFinal analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in ...Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht, Isabel Sevilla, Frédéric Forget
International Journal of Colorectal Disease. 2017-04-19 - 452 citationsSafety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TR...Howard S. Hochster, Lowell L. Hart, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth
Journal of Clinical Oncology. 2008-07-20
Abstracts/Posters
- Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...Lee S. Schwartzberg, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemothera...2019 ASCO Annual Meeting - 6/1/2019
- Eflapegrastim, a novel and potent long-acting GCSF for reducing chemotherapy-induced neutropenia: Integrated results from two phase III trials in breast cancer patients.2019 ASCO Annual Meeting - 6/1/2019
- 7th Community Oncology ConferenceGlobal Academy for Medical Education (Elsevier), Las Vegas, Nevada - 3/30/2012
Press Mentions
- Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)November 4th, 2024
- Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)November 4th, 2024
- Freenome Adds Renown Health as Partner for the Sanderson StudyMarch 28th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: